Japan Approvals Include Keytruda, First Asia Nod for Iclusig

A large batch of new drugs, indications and formulations just granted approval in Japan includes Keytruda and the first marketing authorization in Asia for Ariad's Iclusig.

Approved

Ariad Pharmaceuticals Inc.'s Iclusig (ponatinib) has been approved in Japan for second-line use in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) through Asian licensee Otsuka Pharmaceutical Co. Ltd.

A 15 mg tablet formulation of the oral kinase inhibitor is indicated for CML patients resistant or intolerant to previous...

More from Approvals

More from Product Reviews